Prognostic impact of CD109 expression in myxofibrosarcoma

Emori, Makoto; Tsukahara, Tomohide; Murata, Kenji; Sugita, Shintaro; Sonoda, Tomoko; Kaya, Mitsunori; Soma, Tamotsu; Sasaki, Masanori; Nagoya, Satoshi; Hasegawa, Tadashi; Wada, Takuro; Sato, Noriyuki; Yamashita, Toshihiko

doi:10.1002/jso.23934

Cited by 27 publications

(41 citation statements)

References 23 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…b) . Moreover, studies show that CD109 subcellular localization varies among cancer types, with localization on the cell surface of tumor cells in most cancers, including skin SCC and glioblastoma, but diffuse expression observed throughout the cytoplasm of tumor cells in some types of sarcomas . Our IHC data using an anti‐CD109 monoclonal antibody confirmed CD109 expression on the seminoma cell surface (Fig.…”

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorssupporting

confidence: 74%

“…4). [14][15][16][17][18][19]41,42 A controversial exception is urothelial carcinoma of the urinary bladder, where CD109 expression inversely correlated with poor prognosis in patients in our study (Table 1). 40 Conversely, there was no significant difference in prognosis between CD109-high and -low patients with SCCs (Table 1 and Fig.…”

Section: Cd109 Is Secreted In Its Truncated Form or As A Component Ofmentioning

confidence: 55%

“…Previous reports (Table ) and our analyses using The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) demonstrate that patients with higher expression of CD109 (CD109‐high) have a significantly worse prognosis than those with lower expression of CD109 (CD109‐low) in various malignant tumors, such as those associated with glioma, glioblastoma, breast ductal carcinoma, lung, gastric, colorectal, and pancreatic adenocarcinomas, as well as urothelial carcinoma of the urinary bladder, hepatocellular carcinoma, epithelioid sarcoma, myxofibrosarcoma, and diffuse large B‐cell lymphoma (Table and Fig. ) . A controversial exception is urothelial carcinoma of the urinary bladder, where CD109 expression inversely correlated with poor prognosis in patients in our study (Table ) .…”

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorsmentioning

confidence: 67%

“…High levels of CD109 expression have been detected in various tumor‐cell lines and tumor tissues, including those associated with squamous cell carcinomas (SCCs) of the lung, esophagus, uterus, and oral cavity, adenocarcinomas of the lung and pancreas, breast cancer, glioblastoma, hepatocellular carcinoma, urothelial carcinoma of the urinary bladder, and several types of sarcomas (Table ) . Immunohistochemical (IHC) analyses revealed elevated CD109 expression on tumor cells (Fig.…”

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorsmentioning

confidence: 99%

“…Although CD109 expression is significantly higher in lower-grade SCCs or urothelial carcinomas of the urinary bladder relative to that in higher-grade SCCs or urothelial carcinomas, respectively, 20,24,[26][27][28]40 its expression is significantly higher in higher-grade glioma, ductal carcinoma of the breast, nonsmall cell carcinomas of the lung, hepatocellular carcinoma, epithelioid sarcoma, and myxofibrosarcoma as compared with that in lower-grade tumors, respectively. 14,[16][17][18]35,41 Additionally, CD109 expression in normal tissues is strictly controlled and specifically occurs in myoepithelial cells of the mammary, lacrimal, salivary, and bronchial glands, basal cells of the prostate and bronchial epithelia and epidermis, seminiferous tubules of testis, and osteoblasts and…”

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorsmentioning

confidence: 99%

See 4 more Smart Citations

CD109: a multifunctional GPI‐anchored protein with key roles in tumor progression and physiological homeostasis

Mii

Enomoto

Shiraki

et al. 2019

Pathology International

View full text Add to dashboard Cite

CD109 is a glycosylphosphatidylinositol‐anchored glycoprotein and a member of the α2‐macroglobulin/C3,C4,C5 family of thioester‐containing proteins first identified as being expressed on blood cells, including activated T cells and platelets, and a subset of CD34 + bone marrow cells containing megakaryocyte progenitors. Although CD109 carries the biallelic platelet‐specific alloantigen Gov, the physiological functions or roles of CD109 in human disease remain largely unknown. It was recently demonstrated that CD109 is expressed in many malignant tumors, including various squamous cell carcinomas and adenocarcinomas, and plays a role as a multifunctional coreceptor. CD109 reportedly associates with transforming growth factor (TGF)‐β receptors and negatively regulates TGF‐β signaling in keratinocytes. Additionally, CD109 is potentially related to signal transducer and activator of transcription‐3 signaling and aberrant cell proliferation. In this review, we describe recent evidence of CD109‐specific significance in malignant tumors shown in mouse models and human tissues. Furthermore, we discuss the physiological functions of CD109 in vitro and in vivo, including results of phenotype analyses of CD109‐deficient mice exhibiting epidermal hyperplasia and osteopenia.

show abstract

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorssupporting

confidence: 74%

Section: Cd109 Is Secreted In Its Truncated Form or As A Component Ofmentioning

confidence: 55%

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorsmentioning

confidence: 67%

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorsmentioning

confidence: 99%

Section: Cd109 Is a Membrane Protein Expressed In Malignant Tumorsmentioning

confidence: 99%

See 3 more Smart Citations

CD109: a multifunctional GPI‐anchored protein with key roles in tumor progression and physiological homeostasis

Mii

Enomoto

Shiraki

et al. 2019

Pathology International

View full text Add to dashboard Cite

show abstract

Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma

et al. 2021

View full text Add to dashboard Cite

Background Various biomarkers are being developed for the early diagnosis of cancer and for predicting its prognosis. The aim of this study is to evaluate the diagnostic significance of serum CD109 in head and neck squamous cell carcinoma (HNSCC). Methods The serum CD109 levels in a total of 112 serum samples collected before and after surgery from 56 HNSCC patients were analyzed with an enzyme‐linked immunosorbent assay (ELISA). The clinical factor that showed a statistically significant association with both the preoperative serum CD109 level, and the CD109 index: which was defined as the ratio of the preoperative serum CD109 level to the postoperative serum CD109 level, were assessed. The correlations between the serum CD109 levels and lymph node density (LND), pathological features such as lymphatic invasion, and serum SCC antigen levels were also assessed. Results The ELISA measurement revealed that preoperative serum CD109 levels were elevated in patients with node metastasis‐positive and stage IV disease, in comparison to those with node metastasis‐negative and Stage I+II+III disease, respectively. A multiple regression analysis indicated that serum CD109 level was significantly associated with the node metastasis status. A Spearman's rank correlation analysis also revealed a positive correlation between the preoperative serum CD109 level and LND. Furthermore, the probabilities of the overall and relapse‐free survival were significantly lower in patients with a preoperative serum CD109 level of ≥38.0 ng/ml and a CD109 index of ≥1.6, respectively, than in others. There was no significant correlation between the serum CD109 and SCC antigen levels. Conclusions The serum CD109 levels were elevated in patients with advanced stage disease, reflecting the node metastasis status. CD109 in sera could be a novel prognostic marker for HNSCC involving lymph node metastasis.

show abstract

Soft tissue myxofibrosarcoma: A clinico‐pathological analysis of a series of 75 patients with emphasis on the epithelioid variant

Scoccianti

Ranucci

Frenos

et al. 2016

Journal of Surgical Oncology

View full text Add to dashboard Cite

Our experience confirms the difficulties in obtaining wide margins in myxofibrosarcoma and the high rate of recurrence. Local recurrences did not significantly affect survival and a limb-sparing approach can be chosen also in recurrences. Patients affected by the epithelioid variant showed a worse prognosis. Chemotherapy should be considered as adjuvant treatment in this subtype. J. Surg. Oncol. 2016;114:50-55. © 2016 Wiley Periodicals, Inc.

show abstract

Prognostic impact of CD109 expression in myxofibrosarcoma

Abstract: Immunohistochemical CD109 expression in myxofibrosarcoma was associated with poor prognosis.

Cited by 27 publications

References 23 publications

CD109: a multifunctional GPI‐anchored protein with key roles in tumor progression and physiological homeostasis

CD109: a multifunctional GPI‐anchored protein with key roles in tumor progression and physiological homeostasis

Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma

Soft tissue myxofibrosarcoma: A clinico‐pathological analysis of a series of 75 patients with emphasis on the epithelioid variant

Contact Info

Product

Resources

About